Aminoglycoside dosing in patients by kidney function and area under the curve: The Sawchuk-Zaske dosing method revisited in the era of obesity

Diagnostic Microbiology and Infectious Disease

Volumn 78, Issue 2, 2014, Pages 178-187

  Pai, Manjunath P ^a   Rodvold, Keith A ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Amikacin; Aminoglycosides; Antimicrobial; Gentamicin; Obese; Obesity; Therapeutic Drug Monitoring; Tobramycin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; DAPTOMYCIN; GENTAMICIN; TELAVANCIN; TOBRAMYCIN; VANCOMYCIN;

ACUTE KIDNEY FAILURE; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY SIZE; BODY SURFACE; BODY WEIGHT; CLINICAL DECISION MAKING; COCKCROFT GAULT EQUATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG MONITORING; GLOMERULUS FILTRATION RATE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; KIDNEY FUNCTION; KIDNEY PLASMA FLOW; LEAN BODY WEIGHT; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OBESITY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SAWCHUK ZASKE DOSING METHOD; URINARY TRACT INFECTION;

AMIKACIN; AMINOGLYCOSIDES; ANTIMICROBIAL; GENTAMICIN; OBESE; OBESITY; THERAPEUTIC DRUG MONITORING; TOBRAMYCIN;

ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DRUG MONITORING; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; OBESITY;

EID: 84892488691     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2013.10.011     Document Type: Article

References (70)

1. Aarons L., Vozeh S., Wenk M., Weiss P., Follath F. Population pharmacokinetics of tobramycin. Br J Clin Pharmacol 1989, 28(3):305-314.
2. Ababneh M., Harpe S., Oinonen M., Polk R.E. Trends in aminoglycoside use and gentamicin-resistant gram-negative clinical isolates in US academic medical centers: implications for antimicrobial stewardship. Infect Control Hosp Epidemiol 2012, 33(6):594-601.
3. Adelman M., Evans E., Schentag J.J. Two-compartment comparison of gentamicin and tobramycin in normal volunteers. Antimicrob Agents Chemother 1982, 22(5):800-804.
4. Atkinson A.J., Huang S.M. Nephropharmacology: drugs and the kidney. Clin Pharmacol Ther 2009, 86(5):453-456.
5. Avent M.L., Rogers B.A., Cheng A.C., Paterson D.L. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity. Intern Med J 2011, 41(6):441-449.
6. Barclay M.L., Begg E.J., Hickling K.G. What is the evidence for once-daily aminoglycoside therapy?. Clin Pharmacokinet 1994, 27(1):32-48.
7. Bauer L.A., Blouin R.A., Griffen W.O., Record K.E., Bell R.M. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm 1980, 37(4):519-522.
8. Bauer L.A., Edwards W.A., Dellinger E.P., Simonowitz D.A. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983, 24(5):643-647.
9. Begg E.J., Barclay M.L. Aminoglycosides-50 years on. Br J Clin Pharmacol 1995, 39(6):597-603.
10. Begg E.J., Barclay M.L., Duffull S.B. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol 1995, 39(6):605-609.
11. Begg E.J., Barclay M.L., Kirkpatrick C.M. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 2001, 52(Suppl 1):35S-43S.
12. Brater D.C. Drug dosing in patients with impaired renal function. Clin Pharmacol Ther 2009, 86(5):483-489.
13. Blouin R.A., Mann H.J., Griffen W.O., Bauer L.A., Record K.E. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 1979, 26(4):508-512.
14. Bulger R.J., Sidell S., Kirby W.M. Laboratory and clinical studies of gentamicin, new broad-spectrum antibiotic. Ann Intern Med 1963, 59:593-604.
15. Chagnac A., Herman M., Zingerman B., Erman A., Rozen-Zvi B., Hirsh J., et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. Nephrol Dial Transplant 2008, 23(12):3946-3952.
16. Chan R.A., Benner E.J., Hoeprich P.D. Gentamicin therapy in renal failure: a nomogram for dosage. Ann Intern Med 1972, 76(5):773-778.
17. Chuck S.K., Raber S.R., Rodvold K.A., Areff D. National survey of extended-interval aminoglycoside dosing. Clin Infect Dis 2000, 30(3):433-439.
18. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16(1):31-41.
19. Conil J.M., Georges B., Ruiz S., Rival T., Seguin T., Cougot P., et al. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations. Br J Clin Pharmacol 2011, 71(1):61-71.
20. Contrepois A., Brion N., Garaud J.J., Faurisson F., Delatour F., Levy J.C., et al. Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans. Antimicrob Agents Chemother 1985, 27(4):520-524.
21. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991;27(Suppl C):29-40.
22. Cubicin®, Daptomycin for injection. Full prescribing information. Cubist Pharmaceuticals, Inc., Lexington, MA, 2010.
23. Cutler R.E., Gyselynck A., Sleet W., Forrey A. Correlation of serum creatinine concentrations and gentamicin half-life. JAMA 1972, 219(8):1037-1041.
24. Darrell J.H., Waterworth P.M. Dosage of gentamicin for pseudomonas infections. Br Med J 1967, 2(5551):535-537.
25. Dahlgren J.G., Anderson E.T., Hewitt W.L. Gentamicin blood levels: a guide to nephrotoxicity. Antimicrob Agents Chemother 1975, 8(1):58-62.
26. Delattre I.K., Musuamba F.T., Jacqmin P., Taccone F.S., Laterre P.F., Verbeeck R.K., et al. Population pharmacokinetics of four β-lactams in critically ill septic patients comedicated with amikacin. Clin Biochem 2012, 45(10-11):780-786.
27. Demczar D.J., Nafziger A.N., Bertino J.S. Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing. Antimicrob Agents Chemother 1997, 41(5):1115-1119.
28. Dettli L.C. Drug dosage in patients with renal disease. Clin Pharmacol Ther 1974, 16(1):274-280.
29. Diem K, Lentner C. Documenta Geigy. Scientific Tables, 7th ed. Basel, Switzerland, J.R. Giegy, 1970:711.
30. Drusano G.L., Ambrose P.G., Bhavnani S.M., Bertino J.S., Nafziger A.N., Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis 2007, 45(6):753-760.
31. Drusano G.L., Louie A. Optimization of aminoglycoside therapy. Antimicrob Agents Chemother 2011, 55(6):2528-2531.
32. Earley A., Miskulin D., Lamb E.J., Levey A.S., Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012, 156(11):785-795.
33. Flegal K.M., Carroll M.D., Kuczmarski R.J., Johnson C.L. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998, 22(1):39-47.
34. Flegal K.M., Carroll M.D., Kit B.K., Ogden C.L. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012, 307(5):491-497.
35. Frische S. Glomerular filtration rate in early diabetes: ongoing discussions of causes and mechanisms. J Nephrol 2011, 24(5):537-540.
36. Gaspari F, Perico N, Remuzzi G. Measurement of glomerular filtration rate. Kidney Int 1997;63(Suppl):S151-4.
37. Gentamicin sulfate, injection, USP. 2005. Full prescribing information. Hospira, Inc., Lake Forest, IL.
38. Hull J.H., Sarubbi F.A. Gentamicin serum concentrations: pharmacokinetic predictions. Ann Intern Med 1976, 85(2):183-189.
39. Inciardi J.F., Batra K.K. Nonparametric approach to population pharmacokinetics in oncology patients receiving aminoglycoside therapy. Antimicrob Agents Chemother 1993, 37(5):1025-1027.
40. Inclan G., Suarez E., Calvo R., Aguirre C., Macheras P., Gazouli M., et al. Bicompartmental kinetics of tobramycin analysed with a wide range of covariates. Int J Antimicrob Agents 2005, 26(4):304-311.
41. Janmahasatian S., Duffull S.B., Ash S., Ward L.C., Byrne N.M., Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005, 44(10):1051-1065.
42. Jao R.L., Jackson G.G. Clinical experience with gentamicin in gram-negative infections. Antimicrob Agents Chemother 1963, 161:148-152.
43. Jelliffe R.W., Jelliffe S.M. Estimation of creatinine clearance from changing serum-creatinine levels. Lancet 1971, 2(7726):710.
44. Lesar T.S., Rotschafer J.C., Strand L.M., Solem L.D., Zaske D.E. Gentamicin dosing errors with four commonly used nomograms. JAMA 1982, 248(10):1190-1193.
45. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150(9):604-612.
46. Moore R.D., Lietman P.S., Smith C.R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155(1):93-99.
47. Mosteller R.D. Simplified calculation of body-surface area. N Engl J Med 1987, 317(17):1098.
48. Munita J.M., Arias C.A., Murray B.E. Enterococcal endocarditis: can we win the war?. Curr Infect Dis Rep 2012, 14(4):339-349.
49. Nicolau D.P., Freeman C.D., Belliveau P.P., Nightingale C.H., Ross J.W., Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995, 39(3):650-655.
50. Noone P., Parsons T.M., Pattison J.R., Slack R.C., Garfield-Davies D., Hughes K. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. Br Med J 1974, 1(5906):477-481.
51. Park E.J., Pai M.P., Dong T., Zhang J., Ko C.W., Lawrence J., et al. The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults. Ann Pharmacother 2012, 46(3):317-328.
52. Pai M.P., Paloucek F.P. The origin of the "ideal" body weight equations. Ann Pharmacother 2000, 34(9):1066-1069.
53. Pai M.P. Estimating the glomerular filtration rate in obese adult patients for drug dosing. Adv Chronic Kidney Dis 2010, 17(5):e53-62.
54. Pai M.P., Nafziger A.N., Bertino J.S. Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. Antimicrob Agents Chemother 2011, 55(9):4006-4011.
55. Pai M.P. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy 2012, 32(9):856-868.
56. Romano S., dez de Gatta MM F., Calvo M.V., Caballero D., Dominguez-Gil A., Lanao J.M. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother 1999, 44(2):235-242.
57. Rosario M.C., Thomson A.H., Jodrell D.I., Sharp C.A., Elliott H.L. Population pharmacokinetics of gentamicin in patients with cancer. Br J Clin Pharmacol 1998, 46(3):229-236.
58. Sarubbi F.A., Hull J.H. Amikacin serum concentrations: prediction of levels and dosage guidelines. Ann Intern Med 1978, 89(5 Pt 1):612-618.
59. Sawchuk R.J., Zaske D.E. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm 1976, 4(2):183-195.
60. Schwartz S.N., Pazin G.J., Lyon J.A., Ho M., Pasculle A.W. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis 1978, 138(4):499-505.
61. Sketris I., Lesar T., Zaske D.E., Cipolle R.J. Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol 1981, 21(7):288-293.
62. Spruill W.J., Wade W.E., Cobb H.H. Continuing the use of the Cockcroft-Gault equation for drug dosing in patients with impaired renal function. Clin Pharmacol Ther 2009, 86(5):468-470. (PubMed PMID: 19844221).
63. Stevens L.A., Levey A.S. Use of the MDRD study equation to estimate kidney function for drug dosing. Clin Pharmacol Ther 2009, 86(5):465-467.
64. Stevens L.A., Claybon M.A., Schmid C.H., Chen J., Horio M., Imai E., et al. Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney Int 2011, 79(5):555-562.
65. Tod M., Lortholary O., Seytre D., Semaoun R., Uzzan B., Guillevin L., et al. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults. Antimicrob Agents Chemother 1998, 42(4):849-856.
66. Toutain P.L., Bousquet-Mélou A. Volumes of distribution. J Vet Pharmacol Ther 2004, 27(6):441-453.
67. Urakami Y., Kimura N., Okuda M., Inui K. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 2004, 21(6):976-981.
68. Vancomycin hydrochloride, vancomycin hydrochloride for injection. Full prescribing information. Baxter Healthcare Corporation, Deerfeild, IL, 2008.
69. Vibativ®, Televancin for injection. Full prescribing Information. Theravance, Inc. South San Francisco, CA, 2012.
70. Xuan D., Nicolau D.P., Nightingale C.H. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing. Int J Antimicrob Agents 2004, 23(3):291-295.